More on CMPS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+4.9% Growth)
- Ratings (9.5 Score)

Upcoming Events

- Earnings (7/30/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

COMPASS Pathways plc (NQ:CMPS)
Delayed: 12.35 -0.08 (0.64%)
Prev. Close $12.43  
Open$12.47 
52 Wk High$ 
52 Wk Low$ 
Day High$13.04 
Day Low$12.02 
P/E N/A  
EPS$ 
Volume7,160,373 

Friends, Peers and Foes (?): XENE, GHRS, DFTX, SPRO, DSGN (more...)

Jul 16, 2026 06:35 AM Compass Pathways study finds COMP360 support differs from psychotherapy
Jul 16, 2026 06:35 AM Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
Jul 13, 2026 01:04 PM FDA sets public hearing on psychedelics for September 14, Jefferies sees FDA willing to move on COMP360
Jul 13, 2026 06:26 AM TD Cowen Reiterates Buy Rating on Compass Pathways (CMPS)
Jul 9, 2026 06:49 AM H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS)
Jul 8, 2026 09:42 AM Evercore ISI Upgrades Compass Pathways (CMPS) to Outperform
Jul 8, 2026 06:49 AM Canaccord Reiterates Buy Rating on Compass Pathways (CMPS)
Jul 7, 2026 04:33 PM Compass Pathways (CMPS) PT Raised to $21 at Stifel
Jul 7, 2026 03:53 PM TD Cowen on Compass Pathways (CMPS): 'We think DEA reclassification to schedule 3 after approval is likely'
Jul 7, 2026 03:52 PM Wolfe Research on Compass Pathways (CMPS): 'we expect the stock to regain strong momentum after this pullback'
View All Articles

Entities mentioned with CMPS

View All Entities